Biomedical Engineering Reference
In-Depth Information
[2]
Burkly, L., Hession, C., Ogata, L.
et al., Expression of relB is required for the
development of thymic medulla and dendritic cells,
Nature,
373, 531, 1995.
[3]
Zuklys, S., Balciunaite, G., Agarwal, A.
et al., Normal thymic architecture and
negative selection are associated with AIRE expression, the gene defective in the
autoimmune-polyendocrinopathy-candidiasis-ectodermal dystrophy (APECED),
J.
Immunol.,
165, 1976, 2000.
[4]
Chin, R.K., Lo, J.C., Kim, O.
et al., Lymphotoxin pathway directs thymic AIRE
expression,
Nat. Immunol.,
4, 1121, 2003.
[5]
Grech, A.P., Riminton, D.S., Gabor, M.J.
et al., Increased thymic B cells but main-
tenance of thymic structure, T cell differentiation and negative selection in lympho-
toxin-alpha and TNF gene-targeted mice,
Dev. Immunol.,
8, 61, 2000.
[6]
Jimi, E. and Ghosh, S., Role of nuclear factor-kappaB in the immune system and
bone,
Immunol. Rev.,
208, 80, 2005.
[7]
Dougall, W.C., Glaccum, M., Charrier, K.
et al., RANK is essential for osteoclast
and lymph node development,
Genes Dev.,
13, 2412, 1999.
[8]
Naito, A., Azuma, S., Tanaka, S.
et al., Severe osteopetrosis, defective interleukin-1
signalling and lymph node organogenesis in TRAF6-deficient mice,
Genes Cells,
4,
353, 1999.
[9]
Wong, B.R., Josien, R., Lee, S.Y.
et al., The TRAF family of signal transducers
mediates NF-kappaB activation by the TRANCE receptor,
J. Biol. Chem.,
273, 28355,
1998.
[10]
Lomaga, M.A., Yeh, W.C., Sarosi, I.
et al., TRAF6 deficiency results in osteopetrosis
and defective interleukin-1, CD40, and LPS signaling,
Genes Dev.,
13, 1015, 1999.
[11]
Darnay, B.G., Haridas, V., Ni, J.
et al., Characterization of the intracellular domain
of receptor activator of NF-kappaB (RANK). Interaction with tumor necrosis factor
receptor-associated factors and activation of NF-kappaB and c-Jun N-terminal kinase,
J. Biol. Chem.,
273, 20551, 1998.
[12]
Franzoso, G., Carlson, L., Xing, L.
et al., Requirement for NF-kappaB in osteoclast
and B-cell development,
Genes Dev.,
11, 3482, 1997.
[13]
Iotsova, V., Caamano, J., Loy, J.
et al., Osteopetrosis in mice lacking NF-kappaB1
and NF-kappaB2,
Nat. Med.,
3, 1285, 1997.
[14]
Aya, K., Alhawagri, M., Hagen-Stapleton, A.
et al., NF-(kappa)B-inducing kinase
controls lymphocyte and osteoclast activities in inflammatory arthritis,
J. Clin. Invest.,
115, 1848, 2005.
[15]
Novack, D.V., Yin, L., Hagen-Stapleton, A.
et al., The IkappaB function of NF-kappaB2
p100 controls stimulated osteoclastogenesis,
J. Exp. Med.,
198, 771, 2003.
[16]
Chaisson, M.L., Branstetter, D.G., Derry, J.M.
et al., Osteoclast differentiation is
impaired in the absence of inhibitor of kappa B kinase alpha,
J. Biol. Chem.,
279,
54841, 2004.
[17]
Ruocco, M.G., Maeda, S., Park, J.M.
et al., I{kappa}B kinase (IKK){beta}, but not
IKK{alpha}, is a critical mediator of osteoclast survival and is required for inflam-
mation-induced bone loss,
J. Exp. Med.,
201, 1677, 2005.
[18]
Jimi, E., Aoki, K., Saito, H.
et al., Selective inhibition of NF-kappa B blocks osteo-
clastogenesis and prevents inflammatory bone destruction in vivo,
Nat. Med.,
10, 617,
2004.
[19]
Dai, S., Hirayama, T., Abbas, S.
et al., The IkappaB kinase (IKK) inhibitor, NEMO-
binding domain peptide, blocks osteoclastogenesis and bone erosion in inflammatory
arthritis,
J. Biol. Chem.,
279, 37219, 2004.
[20]
Mebius, R.E., Organogenesis of lymphoid tissues,
Nat. Rev. Immunol.,
3, 292, 2003.
